Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.40 |
| ▸ | PGR | P06401 | 3/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | JUN | P05412 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17634231 | 0.90 | BRD4 (0.47) | BRD4PGRCA2CREBBPKMT2A | |
| SCHEMBL17634230 | 0.86 | BRD4 (0.39) | BRD4PGRACE2CA2CREBBP | |
| SCHEMBL17633653 | 0.86 | BRD4 (0.43) | BRD4PGRACE2JUNNFKB1 | |
| SCHEMBL17633666 | 0.83 | CYP2C19 (0.43) | BRD4PGRCA2GSK3BKMT2A | |
| SCHEMBL17634259 | 0.83 | ABL1 (0.43) | BRD4 | |
| SCHEMBL17634084 | 0.82 | PARP1 (0.49) | BRD4PGRCA2CREBBPGSK3B | |
| SCHEMBL17634149 | 0.78 | BRD4 (0.46) | BRD4PGRCA2CREBBPGSK3B | |
| SCHEMBL17634206 | 0.78 | BRD4 (0.51) | BRD4PGRCREBBPKMT2A | |
| SCHEMBL17634188 | 0.75 | BRD4 (0.44) | BRD4PGRCREBBP | |
| SCHEMBL17634129 | 0.75 | BRD4 (0.46) | BRD4PGRCA2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197900-B1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME (US) | 2020-02-12 | — | — | EP | disclosed |
| US-9969752-B2 | Inhibitors of HIF prolyl hydroxylase | MERCK SHARP & DOHME CORP. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170233412-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-17 | — | — | US | disclosed |
| EP-3197900-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | Merck Sharp & Dohme Corp. (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016049099-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233412-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | BRD4 3617/4885PGR 1351/4885ACE2 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.